Abbott’s investigational treatment for advanced Parkinson’s disease demonstrates positive results Abbott announced the results from a Stage 3 trial evaluating the business’s investigational compound for advanced Parkinson’s disease, levodopa-carbidopa intestinal gel . The analysis showed that individuals treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in off time in comparison to levodopa-carbidopa immediate release tablets, without raising troublesome dyskinesia. Off time refers to the periods of poor flexibility, slowness and stiffness experienced by sufferers with Parkinson’s disease levitra online .
There have been no reports of blood clots in virtually any of the 101 patients. Related StoriesACC's public reporting system provides information regarding hospitals' performanceStudy: Post medical center syndrome is significant risk element for sufferers undergoing elective surgeryGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanning’We are pleased with the improvement of ABSORB and the encouraging data we continue steadily to see from the trial in the complete cohort of more than 100 sufferers,’ said Patrick W.